Bruno A Marichal-Cancino

List of Publications by Year
in descending order

37 papers	619 citations	687335 13 h-index	642715 23 g-index
37 all docs	37 docs citations	37 times ranked	692 citing authors

#	Article	IF	Citations
1	The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling. Life Sciences, 2022, 301, 120596.	4.3	7
2	1-Boc-Piperidine-4-Carboxaldehyde Prevents Binge-Eating Behaviour and Anxiety in Rats. Pharmacology, 2021, 106, 305-315.	2.2	3
3	The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena. Neuroscience Bulletin, 2021, 37, 1493-1509.	2.9	13
4	The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1223-1235.	3.3	1
5	A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Review of Neurotherapeutics, 2021, 21, 1035-1050.	2.8	1
6	Blockade of GPR55 in dorsal periaqueductal gray produces anxiety-like behaviors and evocates defensive aggressive responses in alcohol-pre-exposed rats. Neuroscience Letters, 2021, 764, 136218.	2.1	7
7	NPY-Y1 receptors in dorsal periaqueductal gray modulate anxiety, alcohol intake, and relapse in Wistar rats. Pharmacology Biochemistry and Behavior, 2020, 199, 173071.	2.9	10
8	Advances in Neurobiology and Pharmacology of GPR12. Frontiers in Pharmacology, 2020, 11, 628.	3.5	14
9	Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats. Journal of Vascular Research, 2020, 57, 152-163.	1.4	14
10	Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows. Current Neuropharmacology, 2020, 18, 790-808.	2.9	4
11	The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms. CNS and Neurological Disorders - Drug Targets, 2020, 19, 344-359.	1.4	11
12	Functional Characterization of the Prejunctional Receptors Mediating the Inhibition by Ergotamine of the Rat Perivascular Sensory Peptidergic Drive. ACS Chemical Neuroscience, 2019, 10, 3173-3182.	3.5	6
13	Antimicrobial and antibiofilm activity of biopolymer-Ni, Zn nanoparticle biocomposites synthesized using R. mucilaginosa UANL-001L exopolysaccharide as a capping agent . International Journal of Nanomedicine, 2019, Volume 14, 2557-2571.	6.7	34
14	Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Current Neuropharmacology, 2019, 17, 947-960.	2.9	25
15	Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 25-41.	3.3	74
16	Î²-Adrenoceptor Blockade for Infantile Hemangioma Therapy: Do Î²₃-Adrenoceptors Play a Role?. Journal of Vascular Research, 2018, 55, 159-168.	1.4	16
17	Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of Î±2-adrenoceptors and 5-HT1 receptors. Journal of Headache and Pain, 2018, 19, 40.	6.0	6
18	Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. Frontiers in Pharmacology, 2018, 9, 1496.	3.5	67

#	Article	IF	Citations
19	Possible role of hippocampal GPR55 in spatial learning and memory in rats. Acta Neurobiologiae Experimentalis, 2018, 78, 41-50.	0.7	25
20	Possible role of hippocampal GPR55 in spatial learning and memory in rats. Acta Neurobiologiae Experimentalis, 2018, 78, 41-50.	0.7	13
21	Olcegepant blocks neurogenic and nonâ€neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. British Journal of Pharmacology, 2017, 174, 2001-2014.	5.4	20
22	Advances in the Physiology of GPR55 in the Central Nervous System. Current Neuropharmacology, 2017, 15, 771-778.	2.9	74
23	Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases. BioMed Research International, 2016, 2016, 1-17.	1.9	18
24	Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm. Behavioural Pharmacology, 2016, 27, 393-396.	1.7	26
25	Cardiovascular Alterations during the Interictal Period in Awake and Pithed Amygdalaâ€Kindled Rats. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 165-172.	2.5	4
26	mGluR1/5 activation in the lateral hypothalamus increases food intake via the endocannabinoid system. Neuroscience Letters, 2016, 631, 104-108.	2.1	12
27	Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow. European Journal of Pharmacology, 2016, 773, 85-92.	3.5	4
28	Pharmacological evidence that histamine H3 receptors inhibit the vasodepressor responses by selective stimulation of the rat perivascular sensory CGRPergic outflow. European Journal of Pharmacology, 2015, 754, 25-31.	3.5	10
29	Specific Role of Î±_{2A}â€•and Î±_{2B}â€, but not Î±_{2C}â€, Adrenoceptor Subtypes in the Inhibition of the Vasopressor Sympathetic Outâ€flow in Diabetic Pithed Rats. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 31-38.	2.5	9
30	Role of Preâ€junctional <scp>CB</scp>₁, But not <scp>CB</scp>₂, <scp>TRPV</scp>1 or <scp>GPR</scp>55 Receptors in Anandamideâ€induced Inhibition of the Vasodepressor Sensory <scp>CGRP</scp>ergic Outflow in Pithed Rats. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 240-247.	2.5	10
31	The Role of Pre-junctional D₂-like Receptors Mediating Quinpirole-Induced Inhibition of the Vasodepressor Sensory CGRPergic Out-flow in Pithed Rats. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 174-180.	2.5	8
32	Predominant role of the dopamine D3 receptor subtype for mediating the quinpirole-induced inhibition of the vasopressor sympathetic outflow in pithed rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 393-403.	3.0	8
33	Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. European Journal of Pharmacology, 2013, 721, 168-177.	3.5	23
34	The role of dopamine <scp>D</scp>₂, but not <scp>D</scp>₃ or <scp>D</scp>₄, receptor subtypes, in quinpiroleâ€induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. British Journal of Pharmacology, 2013, 170, 1102-1111.	5.4	13
35	Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935- and rauwolscine-sensitive receptors. European Journal of Pharmacology, 2012, 692, 69-77.	3.5	11
36	Pharmacological evidence that spinal Î±2C- and, to a lesser extent, Î±2A-adrenoceptors inhibit capsaicin-induced vasodilatation in the canine external carotid circulation. European Journal of Pharmacology, 2012, 683, 204-210.	3.5	9

#	Article	IF	Citations
37	The Dopamine Receptors Mediating Inhibition of the Sympathetic Vasopressor Outflow in Pithed Rats: Pharmacological Correlation with the D2-like Type. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 506-512.	2.5	9